Free Trial

YS Biopharma (YSB) Earnings Date, Estimates & Call Transcripts

YS Biopharma logo
Get YS Biopharma Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on YS Biopharma and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

YSB Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

YSB Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

YS Biopharma Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q4 20241-$0.08-$0.08-$0.08
20241-$0.08-$0.08-$0.08
Q1 20251-$0.09-$0.09-$0.09
Q2 20251-$0.08-$0.08-$0.08
Q3 20251-$0.06-$0.06-$0.06
Q4 20251-$0.02-$0.02-$0.02
FY 20254($0.25)($0.25)($0.25)

YS Biopharma Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
1/22/2024Q2 2024--$0.16 -$0.16-$0.16-$13.64M
8/15/2023Q1 2024--$0.10 -$0.10-$0.10-$24.40M

YS Biopharma Earnings - Frequently Asked Questions

YS Biopharma (NASDAQ:YSB) has a recorded annual revenue of $560.76 million.

YS Biopharma (NASDAQ:YSB) has a recorded net income of -$21.17 million. YSB has generated $0.00 earnings per share over the last four quarters.

YS Biopharma's earnings are expected to grow from ($0.45) per share to ($0.25) per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:YSB) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners